Alkermes: Q3 Earnings Snapshot

Alkermes PLC (ALKS) reported Q3 earnings of $16.3M, or 9 cents per share, beating analyst expectations of a 8 cent loss. Revenue was $480.1M, exceeding forecasts of $465.9M. Shares have risen 60% YTD and 46% in the past year.

Original reporting
Published Nov 3, 2026, 12:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alkermes: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$ALKSBullishMed
01

Why it matters

The key tradable information is the explicit EPS and revenue beat versus consensus, which can drive short-term repricing and momentum trading.

02

Market read

Traders can use the reported EPS and revenue beats to assess whether the market’s expectations were too low, but there is no forward guidance detail to anchor a longer-term thesis.

03

What to watch

The article omits cash flow, pipeline/product updates, and any forward guidance, which are often the real drivers of post-earnings repricing.

Relevance 7/10Novelty 7/10Timing: reported Tuesday, before/around the market open depending on local publication time

Background

The article is an AP-generated earnings snapshot for Alkermes’ third quarter, citing analyst expectations from Zacks.

Company-level read

Ticker impact

$ALKSBullishMedium confidence
Context

Alkermes reported Q3 results with revenue of $480.1M and net income of 9 cents per share, both topping expectations.

Expected impact

Likely upward bias as traders price in the earnings beat versus consensus.

Evidence & confidence

The piece is a first-report earnings snapshot with explicit EPS and revenue beats, but it lacks forward-looking guidance, margins, or management commentary that would extend the move.

Market effects

Adds incremental signal of demand and execution strength in specialty pharma/biopharma earnings season, but no sector-wide read-through is provided.

Limited, as the story is company-specific with no broader regional macro or policy linkage.

Low, since it is a single-company earnings snapshot without international regulatory or product milestone context.

Counterpoint

A beat may already be partially reflected given the stock is up sharply year-to-date, so incremental upside could be limited without guidance.

Key entities

  • Alkermes PLC

    Dublin-based drugmaker reporting Q3 earnings results and comparing them to Wall Street expectations.

Related articles

$TAKHighAI 8/10

Awake to the possibilities: a ‘first in class’ narcolepsy drug could be transformational

Takeda's narcolepsy drug Orzeyful (oveporexton), approved by the FDA in 2026, targets the underlying cause of type 1 narcolepsy by activating orexin receptors. The drug, taken twice daily, shows immediate effects but has some side effects. Takeda seeks UK approval. Other companies like Eli Lilly, Alkermes, and Lundbeck are also developing orexin agonists for sleep disorders. (350 characters)

$ALKSMed

H.C. Wainwright raises Alkermes stock price target to $50 on pipeline progress

H.C. Wainwright raised its price target for Alkermes (ALKS) to $50 from $43, citing progress in its clinical pipeline and commercial revenue. The stock is up 63% year-to-date. The firm maintained a Neutral rating. Alkermes recently reported stronger-than-expected Q3 2026 results, with adjusted earnings of $0.09 per share and revenue of $480.1 million. Baird and Wells Fargo also raised their price targets.

$ALKSMed

Alkermes PLC (ALKS) Q3 2026 Earnings Call Highlights: Proprietary Sales Surge 31%

Alkermes PLC (ALKS) reported a 31% surge in proprietary sales for Q3 2026, but R&D and SG&A expenses rose due to the Avadel acquisition and expanded orexin development. LYBALVI's gross-to-net adjustments are expected to reach 45% in 2027, potentially pressuring net sales growth. The company faces competition from Takeda's oveporexton in the narcolepsy market. Alkermes expects to provide full 2027 financial guidance in February, leaving investors with uncertainty.

$ALKSHighAI 8/10

Alkermes (ALKS) Q3 2026 Earnings Call Transcript

Alkermes (ALKS) reported Q3 2026 net sales of $417.3M, up 31% YoY. Key products include VIVITROL ($127.6M), ARISTADA ($103.9M), LYBALVI ($95.9M), and LUMRYZ ($89.9M). Full-year guidance remains unchanged. The company expects continued growth in 2027 and beyond, driven by expanded payer access and new product launches.